FI956279A0 - Förfaranden och mellanprodukter för framställning av 5-/2-(4-(bensoisotiazol-3-yl)-piperazin-1-yl)etyl/-6-kloro-1,3-dihydro-indol-2-on - Google Patents
Förfaranden och mellanprodukter för framställning av 5-/2-(4-(bensoisotiazol-3-yl)-piperazin-1-yl)etyl/-6-kloro-1,3-dihydro-indol-2-onInfo
- Publication number
- FI956279A0 FI956279A0 FI956279A FI956279A FI956279A0 FI 956279 A0 FI956279 A0 FI 956279A0 FI 956279 A FI956279 A FI 956279A FI 956279 A FI956279 A FI 956279A FI 956279 A0 FI956279 A0 FI 956279A0
- Authority
- FI
- Finland
- Prior art keywords
- formula
- alkyl
- compound
- benzoisothiazol
- dihydroindol
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8342993 | 1993-06-28 | ||
| US08/083,429 US5359068A (en) | 1993-06-28 | 1993-06-28 | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| PCT/IB1994/000061 WO1995000510A1 (en) | 1993-06-28 | 1994-04-06 | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| IB9400061 | 1994-04-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI956279A0 true FI956279A0 (sv) | 1995-12-27 |
| FI956279L FI956279L (sv) | 1995-12-27 |
| FI119372B FI119372B (sv) | 2008-10-31 |
Family
ID=22178273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI956279A FI119372B (sv) | 1993-06-28 | 1995-12-27 | Förfaranden och mellanprodukter för framställning av 5-[ 2-(4-(bensoisotiazol-3-yl)-piperazin-1-yl]etyl]-6-kloro-1,3-dihydro-indol-2-on |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5359068A (sv) |
| EP (1) | EP0706524B1 (sv) |
| JP (1) | JP2667987B2 (sv) |
| AT (1) | ATE277041T1 (sv) |
| CA (1) | CA2166203C (sv) |
| DE (1) | DE69434020T2 (sv) |
| DK (1) | DK0706524T3 (sv) |
| ES (1) | ES2227524T3 (sv) |
| FI (1) | FI119372B (sv) |
| PT (1) | PT706524E (sv) |
| WO (1) | WO1995000510A1 (sv) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3701044B2 (ja) * | 1995-04-24 | 2005-09-28 | 住友精化株式会社 | シアノベンゼンスルフェニルハライドおよびそれを用いる３−置換ベンゾイソチアゾールの製造方法 |
| EP0790236B1 (en) * | 1996-02-13 | 2003-11-19 | Pfizer Inc. | Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| HU229057B1 (en) * | 1996-05-07 | 2013-07-29 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| AU2003260942A1 (en) * | 2002-05-24 | 2003-12-12 | Sun Pharmaceutical Industries Limited | A process for the preparation of oxindole derivatives |
| US7488729B2 (en) | 2002-12-04 | 2009-02-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof |
| WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
| KR20060015750A (ko) * | 2003-06-03 | 2006-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법 |
| US7667037B2 (en) * | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| AU2003285600A1 (en) * | 2003-11-28 | 2005-06-24 | Siddiqui Mohammed Jaweed Mukarram | Process for the preparing ziprasidone monohydrochloride hydrate |
| WO2005061493A2 (en) * | 2003-12-18 | 2005-07-07 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
| CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
| CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| WO2006086779A1 (en) * | 2005-02-11 | 2006-08-17 | Teva Pharmaceutical Industries Ltd. | Amorphous ziprasidone mesylate |
| CA2599391A1 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ziprasidone mesylate |
| WO2006099452A1 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Anhydrous ziprasidone mesylate and a process for its preparation |
| US8097610B2 (en) * | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
| US8119568B2 (en) | 2007-01-26 | 2012-02-21 | Basf Se | 3-amino-1,2-benzisothiazole compounds for combating animal pest II |
| PL391810A1 (pl) | 2010-07-14 | 2012-01-16 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Nowe sole ziprasidonu oraz sposoby ich otrzymywania |
| CN104370850B (zh) * | 2013-08-14 | 2018-02-27 | 上海天慈生物谷生物工程有限公司 | 一种齐拉西酮关键中间体的制备方法 |
| JP2024177597A (ja) * | 2021-11-04 | 2024-12-20 | 日産化学株式会社 | インドール化合物の製造方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721712A (en) * | 1984-06-12 | 1988-01-26 | Pfizer Inc. | 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents |
| US4569942A (en) * | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
| US4690943A (en) * | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
| US4952584A (en) * | 1986-01-11 | 1990-08-28 | Beecham Group P.L.C. | 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful pharmaceutical activity |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| JPH0252042A (ja) * | 1988-08-17 | 1990-02-21 | Hitachi Plant Eng & Constr Co Ltd | 空気の浄化剤及びその製造方法 |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
-
1993
- 1993-06-28 US US08/083,429 patent/US5359068A/en not_active Expired - Lifetime
-
1994
- 1994-04-06 JP JP7502611A patent/JP2667987B2/ja not_active Expired - Fee Related
- 1994-04-06 DK DK94910016T patent/DK0706524T3/da active
- 1994-04-06 AT AT94910016T patent/ATE277041T1/de not_active IP Right Cessation
- 1994-04-06 WO PCT/IB1994/000061 patent/WO1995000510A1/en active IP Right Grant
- 1994-04-06 ES ES94910016T patent/ES2227524T3/es not_active Expired - Lifetime
- 1994-04-06 CA CA002166203A patent/CA2166203C/en not_active Expired - Fee Related
- 1994-04-06 DE DE69434020T patent/DE69434020T2/de not_active Expired - Fee Related
- 1994-04-06 PT PT94910016T patent/PT706524E/pt unknown
- 1994-04-06 EP EP94910016A patent/EP0706524B1/en not_active Expired - Lifetime
-
1995
- 1995-12-27 FI FI956279A patent/FI119372B/sv active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| FI119372B (sv) | 2008-10-31 |
| WO1995000510A1 (en) | 1995-01-05 |
| ES2227524T3 (es) | 2005-04-01 |
| CA2166203A1 (en) | 1995-01-05 |
| ATE277041T1 (de) | 2004-10-15 |
| PT706524E (pt) | 2005-03-31 |
| DE69434020T2 (de) | 2005-09-29 |
| DK0706524T3 (da) | 2005-01-31 |
| FI956279L (sv) | 1995-12-27 |
| CA2166203C (en) | 2001-04-24 |
| DE69434020D1 (de) | 2004-10-28 |
| EP0706524B1 (en) | 2004-09-22 |
| JP2667987B2 (ja) | 1997-10-27 |
| US5359068A (en) | 1994-10-25 |
| EP0706524A1 (en) | 1996-04-17 |
| JPH08506354A (ja) | 1996-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI956279A0 (sv) | Förfaranden och mellanprodukter för framställning av 5-/2-(4-(bensoisotiazol-3-yl)-piperazin-1-yl)etyl/-6-kloro-1,3-dihydro-indol-2-on | |
| GB2263110B (en) | Piperazine derivatives | |
| CA2240136A1 (en) | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | |
| ES2165357T3 (es) | Derivados de metileno-oxiindol y procedimiento de elaboracion. | |
| GR3023174T3 (en) | Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments. | |
| DK0567271T3 (da) | Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| ID26622A (id) | Senyawa-senyawa pengganti 2-benzylamino-2-phenyl-acetamide | |
| ZA941963B (en) | Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process for their preparation | |
| AU9066498A (en) | Substituted 6-alkylphenanthridines | |
| AU544067B2 (en) | Thioamides and amides. treatment of diabetes | |
| TW369528B (en) | Alpha-substituted benzyl heterocyclic derivatives, a process for producing intermediates and containing the same as a fungicide or insecticide active ingredient | |
| ZA941964B (en) | Substituted (arylalkylaminobezyl) aminopropionamide derivatives and process for their preparation | |
| ES2102327A1 (es) | Nuevos derivados de 2,2,6,6-tetrametilpiperidina para utilizarse como agentes estabilizantes para materiales organicos contra la luz, el calor, y la oxidacion. n | |
| CA2058398A1 (en) | 1,4 Benzothiazine-2-Acetic Acid Derivatives, Processes for Production Thereof | |
| DE69405760D1 (de) | 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren | |
| AU2287499A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| HUT71512A (en) | N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them | |
| AU686104B2 (en) | Substituted amidinonaphthyl ester derivatives | |
| AU5110293A (en) | Process for the stereoselective synthesis of 3-substituted 2-thiomethyl propionic acids | |
| AU2178099A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| ES8506662A1 (es) | Procedimiento para la preparacion de derivados de naftaleniltiazol | |
| HUT68806A (en) | Isoxazole carboxylic acid amides, process for producing them and their use | |
| JO1681B1 (en) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119372 Country of ref document: FI |